Mycophenolate mofetil for myasthenia gravis: An open-label pilot study
Open Access
- 9 January 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 56 (1), 97-99
- https://doi.org/10.1212/wnl.56.1.97
Abstract
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.Keywords
This publication has 5 references indexed in Scilit:
- Myasthenia gravisNeurology, 2000
- Myasthenia gravis activities of daily living profileNeurology, 1999
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995